Ann Gelormini

Ann Gelormini serves as the Vice President of Pharmaceutical Development & Manufacturing at Deciphera Pharmaceuticals, where responsibilities include overseeing all CMC Development, manufacturing, and testing for the clinical portfolio and commercial medicines Qinlock® and Romvimza®. Previously, Ann held various leadership roles in chemical development and manufacturing at companies such as Ocular Therapeutix, Entasis Therapeutics, and Aegerion Pharmaceuticals, focusing on the development of clinical candidates and managing regulatory submissions. With a robust educational background that includes a Postdoctoral degree in Total Synthesis from Harvard University and a Ph.D. in Organometallic Chemistry from Case Western Reserve University, Ann has extensive experience in leading cross-functional teams to ensure the successful delivery of high-quality drug substances in compliance with regulatory standards.